Acesso livre
Acesso livre

Emergências e Terapia Intensiva

Comissão Lancet | Especialistas alertam para o aumento da supermedicalização da morte e fazem um chamado para repensar, radicalmente, o modo como a sociedade cuida das pessoas em fase final de vida.

4 Fev, 2022 | 15:16h

Comunicado de imprensa: THE LANCET: Experts warn of the increasing overmedicalization of death, call for radical rethink of how society cares for dying people

Página principal: Lancet Commission on the Value of Death (necessário cadastro gratuito para todos os artigos)

Report of the Lancet Commission on the Value of Death: bringing death back into life

The precariousness of balancing life and death

Ros Taylor: seeing palliative care as relational

Conteúdo relacionado: What would it take to die well? A systematic review of systematic reviews on the conditions for a good death – The Lancet Health Longevity

 

Comentário no Twitter (fio – clique para saber mais)

 


Atualização do consenso de especialistas sobre a classificação SCAI SHOCK do choque cardiogênico.

4 Fev, 2022 | 15:14h

SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021 – JSCAI

Comunicado de imprensa: SCAI releases updated expert consensus to SCAI SHOCK classification – Society for Cardiovascular Angiography and Interventions

Comentários:

SCAI SHOCK: Update Refines Cardiogenic Shock Classification – TCTMD

SCAI Releases Updated Expert Consensus to SCAI SHOCK Classification – American College of Cardiology

 

Comentários no Twitter

 


Estudo observacional | Envolvimento farmacêutico no cuidado de pacientes críticos pode reduzir a utilização de recursos, os eventos adversos medicamentosos e os custos médicos.

4 Fev, 2022 | 15:11h

PHarmacist Avoidance or Reductions in Medical Costs in CRITically Ill Adults: PHARM-CRIT Study – Critical Care Explorations

 

Comentário do autor no Twitter (fio – clique para saber mais)

 


Consenso | Nefrotoxinas e lesão renal aguda.

4 Fev, 2022 | 15:01h

Nephrotoxins and acute kidney injury – The consensus of the Taiwan acute kidney injury Task Force – Journal of the Formosan Medical Association


M-A | Vasopressina e glicocorticoides na parada cardíaca em pacientes internados.

4 Fev, 2022 | 14:56h

Vasopressin and glucocorticoids for in-hospital cardiac arrest: A systematic review and meta-analysis of individual participant data – Resuscitation

Conteúdo relacionado: RCT: Vasopressin + Methylprednisolone increase the likelihood of return of spontaneous circulation compared to placebo in patients with in-hospital cardiac arrest.

 

Comentário no Twitter

 


Revisão | Tratamento multidisciplinar da lesão traqueobrônquica.

4 Fev, 2022 | 14:27h

Multidisciplinary management of tracheobronchial injury – European Respiratory Review


FDA interrompe o uso de anticorpos monoclonais que não funcionam contra a Ômicron.

31 Jan, 2022 | 08:56h

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

Conteúdo relacionado: Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.


Diretrizes ELSO para circuitos de oxigenação extracorpórea para pacientes adultos e pediátricos.

31 Jan, 2022 | 08:47h

ELSO Guidelines for Adult and Pediatric Extracorporeal Membrane Oxygenation Circuits – ASAIO Journal

Conteúdo relacionado: ELSO Guidelines for anticoagulation in adult and pediatric patients using extracorporeal membrane oxygenation (ECMO).

 

Comentário no Twitter

 


Resumo de diretriz | Tratamento dos 10 eventos adversos imunológicos mais comuns em pacientes em imunoterapia.

31 Jan, 2022 | 08:39h

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Artigo original: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Conteúdos relacionados:

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (várias fontes sobre o tema)


Estudo randomizado | Imunoglobulina hiperimune não melhorou os desfechos de pacientes internados com COVID-19.

28 Jan, 2022 | 17:24h

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Comentários:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.